Howard P. Furst, a director of Nivalis Therapeutics, Inc., just received 12,300 options from the company. The strike price of the options received was $7.77, and these expire on September 12, 2026. Furst now owns at least 12,300 options on the company.
Some additional info was provided as follows:
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
The shares shall vest in 12 equal monthly installments commencing on October 12, 2016.
The Reporting Person, a partner in Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities.
The above information was disclo sed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Nivalis Therapeutics, Inc. makes a similar move, sign up!